Original Research Article
Year: 2023 | Month: August | Volume: 10 | Issue: 8 | Pages: 608-618
DOI: https://doi.org/10.52403/ijrr.20230880
The Relationship of CYFRA 21-1 to the Metastatic Process of Advanced Non- Small Cell Lung Carcinoma
Alfiah1, Arif Santoso1,2,3, Irawaty Djaharuddin1,2,3, Erwin Arief11,2,3, Harun Iskandar1,2,3, Nurjannah Lihawa1,2
1Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Hasanuddin University,
Makassar, Indonesia
2Dr.Wahidin Sudirohusodo General Hospital, Makassar, Indonesia
3Hasanuddin University Hospital, Makassar, Indonesia
Corresponding Author: Alfiah Fahrul
ABSTRACT
Lung cancer is a leading cause of death worldwide. Globally, lung cancer is estimated to cause 2.2 million new cases and 1.8 million deaths in 2020. About 85% of total lung cancer cases are estimated to be Non-Small Cell Carcinoma Lung Cancer (NSCLC). Lung cancer itself has several tumor markers because the type of cancer depends on its cell origin where Cytokeratin19 fragment (CYFRA 21-1) is used for squamous cell carcinoma type lung cancer. This study aims to assess the sensitivity of CYFRA 21-1 tumor biomarker examination in advanced non-small cell carcinoma lung cancer. This study was a cross-sectional study in lung cancer patients at Wahidin Sudirohusodo Hospital in the period January- March 2023. Each research subject collected bronchial lavage and serum samples, then tested CYFRA 21-1 levels using the ELISA method. The results showed that in subjects with JPBSK, most diagnoses were made based on the bronchial lavage method (72.7%), diagnosed at an advanced stage (88.5%) with a cytology/histology type of squamous cell carcinoma (43.2%). The research data showed that the serum level of CYFRA 21-1 in NSCLC patients was higher than non-cancer patients (p=0.015). It can be concluded that serum CYFRA 21-1 levels increased significantly in NSCLC subjects when compared to non-cancer.
Keywords: NSCLC, CYFRA 21-1, Bronchial Rinses, Serum
[PDF Full Text]